FARS2 and cardiac hypertrophy: Overall, these findings suggest that AAV9-mediated mitochondrial dynamics intervention could elicit functional and morphological benefits in FARS2 deficiency–related cardiac hypertrophy, highlighting the pathological function of disrupted mitochondrial dynamics and potential therapeutic tactics in cardiac hypertrophy caused by FARS2 deficiency.